Solis Pharms Company Profile
What is the competitive landscape for SOLIS PHARMS
SOLIS PHARMS has five approved drugs.
Drugs and US Patents for Solis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solis Pharms | DAPSONE | dapsone | TABLET;ORAL | 203887-002 | May 6, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solis Pharms | PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride | FOR SOLUTION;ORAL | 202060-001 | Mar 8, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Solis Pharms | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | SOLUTION;ORAL | 075292-001 | Feb 7, 2002 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solis Pharms | PIROXICAM | piroxicam | CAPSULE;ORAL | 074118-001 | Jun 15, 1993 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solis Pharms | DAPSONE | dapsone | TABLET;ORAL | 203887-001 | May 6, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solis Pharms | ELIXOPHYLLIN | theophylline | SOLUTION, ELIXIR;ORAL | 085186-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

